U.S. markets close in 3 hours 32 minutes
  • S&P 500

    4,537.36
    +17.73 (+0.39%)
     
  • Dow 30

    35,649.75
    +192.44 (+0.54%)
     
  • Nasdaq

    15,140.09
    +11.00 (+0.07%)
     
  • Russell 2000

    2,293.70
    +17.79 (+0.78%)
     
  • Crude Oil

    83.77
    +0.81 (+0.98%)
     
  • Gold

    1,784.70
    +14.20 (+0.80%)
     
  • Silver

    24.41
    +0.52 (+2.19%)
     
  • EUR/USD

    1.1654
    +0.0016 (+0.14%)
     
  • 10-Yr Bond

    1.6370
    +0.0020 (+0.12%)
     
  • GBP/USD

    1.3820
    +0.0026 (+0.19%)
     
  • USD/JPY

    114.1800
    -0.1800 (-0.16%)
     
  • BTC-USD

    66,636.28
    +4,028.28 (+6.43%)
     
  • CMC Crypto 200

    1,551.83
    +71.03 (+4.80%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

Bellerophon to Present at the JMP Securities Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, being held June 19-20, 2019, at the St. Regis New York Hotel in New York City.

Bellerophon Presentation Details

Date:

Thursday, June 20

Time:

11:00 AM Eastern Time

Location:

St. Regis New York Hotel, New York, NY

Webcast:

http://wsw.com/webcast/jmp39/blph/

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At Bellerophon:

At LifeSci Advisors:

Fabian Tenenbaum, Chief Executive Officer

Brian Ritchie

(908) 574-4767

(212) 915-2578

britchie@lifesciadvisors.com